Impact BioMedical (IBO) Stock Surges 115% After Merger Amendment Extends Deadline to July 2026

TLDR

• IBO surged over 115% in pre-market trading after filing an SEC Form 8-K with merger amendments
• The end date for its merger with Dr Ashleys Limited has been pushed from March 31 to July 1, 2026
• Impact BioMedical is set to receive 169.56 million PubCo Ordinary Shares, equal to 94.20% of the combined company
• DSS, Inc. — IBO’s parent company — holds 88.87% of IBO on a fully diluted basis and will receive 53,000 shares for hold harmless obligations
• IBO closed at $0.41 before the move, with a 52-week range of $0.36 to $6.17

Impact BioMedical filed a Form 8-K on March 5, 2026, detailing several amendments to its planned merger with Dr Ashleys Bio Labs Limited, a Cayman Islands-based pharmaceutical company.

Impact BioMedical Inc., IBO

The stock shot up over 115% in pre-market trading to $0.85, after closing the prior session at $0.41.

The merger agreement was originally signed on June 21, 2025. The new amendments push the deal’s “End Date” back by three months — from March 31, 2026, to July 1, 2026.

That extension gives both parties more time to meet the conditions needed to close the deal.

One key change in the amended agreement requires IBO to get board approval before entering any new loan agreements ahead of the merger closing.

Under the revised share structure, Impact BioMedical will receive 169,560,000 PubCo Ordinary Shares at closing. That represents 94.20% of the combined company, excluding performance-based shares, CEO compensation shares, and any DSS-related issuances.

Merger Share Structure and DSS Role

DSS, Inc. is IBO’s parent company. It holds approximately 88.87% of IBO on a fully diluted basis, alongside DSS BioHealth Security, Inc.

As part of the amended Transition Arrangement Agreement, DSS will receive 53,000 ordinary shares of Dr Ashleys Limited at closing to cover hold harmless obligations.

An extra 75,000 shares will be issued to DSS if it fully meets its funding obligations under the revised agreement.

The Voting and Support Agreement was also updated. Supporting stockholders now hold a confirmed 92,980,843 IBO shares, representing 88.87% on a fully diluted basis following conversion of preferred shares and promissory notes.

IBO’s Recent Trading History

Prior to Wednesday’s after-hours and Thursday’s pre-market surge, IBO had fallen 71.30% over the past 12 months.

The stock has a 52-week range of $0.36 to $6.17, and was trading just above its 52-week low before the merger news broke.

IBO’s market cap stood at approximately $43.24 million.

The Relative Strength Index (RSI) sits at 39.62, reflecting the stock’s weak technical position heading into this week.

After-hours trading on Wednesday saw IBO rise 86.28% to $0.77 before the pre-market move pushed it above $0.85.

The post Impact BioMedical (IBO) Stock Surges 115% After Merger Amendment Extends Deadline to July 2026 appeared first on CoinCentral.